Organon to supply Hanmi’s 3 combo drugs in Malaysia, Philippines
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three of its combination drugs for cardiovascular and respiratory treatment to Malaysia and the Philippines. Organon will manage the marketing, distribution, and sales in these markets, expanding the companies' partnership in Southeast Asia. This collaboration aims to enhance healthcare access and treatment options in a rapidly growing pharmaceutical market.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Hanmi Pharmaceutical has signed an agreement with global healthcare company Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, while Hanmi will supply the finished products. This partnership aims to expand Hanmi's commercial presence in Southeast Asia and improve access to essential medicines in the region.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Hanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.
Organon & Co stock hits 52-week high at $13.44 By Investing.com
Organon & Co (OGN) stock recently reached a 52-week high of $13.44, representing a 48.89% appreciation over the past year, driven by strategic initiatives and market confidence. Despite this stock performance, the company reported first-quarter results below Wall Street expectations, with adjusted earnings per share of $0.71 and revenue of $1.46 billion, both missing analyst consensus. The revenue decline was primarily attributed to unfavorable pricing, product mix, and significant drops in Women's Health revenue due to decreased Nexplanon sales and reduced demand for oral contraceptives in China.
Organon & Co. (OGN) Leads Mid-Cap Stocks with Low Forward P/E Ra
Organon & Co. (OGN) has been highlighted for its low forward P/E ratio of 3.89, suggesting it may be undervalued despite its current P/E of 14.4x being near its 10-year high. The company has a GF Score™ of 74/100, driven by strong profitability, although it faces challenges in financial strength and growth. Positive insider buying activity further indicates confidence in the company's future prospects, making it an intriguing option for value investors in the healthcare sector.
Organon & Co stock hits 52-week high at $13.44
Organon & Co. (OGN) stock reached a 52-week high of $13.44, reflecting a 48.89% appreciation over the past year due to strategic initiatives and market confidence. Despite this, the company reported first-quarter results below Wall Street expectations, with adjusted earnings and revenue missing consensus, driven by declines in Women’s Health revenue and Nexplanon sales. The revenue drop was attributed to unfavorable pricing, product mix, and reduced demand in key markets.
Organon sees opportunities in China's push for high-quality population development
Organon, a global healthcare company, identifies significant growth opportunities in China, particularly in women's health, fertility support, and chronic disease management. This aligns with China's push for improved population development, a fertility-friendly society, and addressing population aging. China is Organon's second-largest market, and the company plans to deepen its local presence and collaborations to support the nation's healthcare advancements.
VIRGINIA RETIREMENT SYSTEMS ET Al Raises Stock Holdings in Organon & Co. $OGN
Virginia Retirement Systems ET Al significantly increased its stake in Organon & Co. by 1,062.1% in the fourth quarter, now holding 254,500 shares valued at $1.83 million. Other institutional investors like Vanguard Group Inc. and AQR Capital Management LLC also boosted their holdings. Despite this, Organon & Co. recently missed Q1 earnings expectations, and analysts currently maintain a "Reduce" rating with an average target price of $11.40.
OGN - Organon & Co Stock Price and Quote
This article provides comprehensive stock information for Organon & Co. (OGN), including real-time quotes, detailed financial metrics, analyst ratings, and a chronological list of recent news and insider transactions. It highlights the company's performance, key financial indicators like P/E ratio and market cap, and significant corporate events such as earnings reports and M&A activities.
Organon & Co (OGN) Stock Price Quote Today & Current Price Chart
This page provides current trading information for Organon & Co (OGN) stock, listed as a CFD for trading on Capital.com. It details key trading conditions such as spread, overnight funding adjustments, margin requirements, and recent stock performance data. The article also includes a feed of related news and shareholder update investigations concerning Organon & Co.
What Sparked Organon's Recent Stock Surge
Organon & Co. (NYSE: OGN) shares surged by 7.71% to $8.10 after an independent audit review concluded no financial restatements or evidence of improper conduct were found, removing a significant overhang. Despite this positive development, the company faces ongoing operational challenges, including declining revenue, a Q4 2025 net loss, flat 2026 guidance, and a high debt load. Investors face a mixed outlook, balancing the de-risked balance sheet and biosimilar growth potential against headwinds from legacy product declines and financial constraints.
Organon stock surges 31% on sweetened $13 billion takeover offer from Sun Pharma
Organon stock surged 31% following a sweetened $13 billion takeover offer from Sun Pharma. Sun Pharma's revised bid values Organon shares at a significant premium, reflecting its strategic interest in the company. This acquisition aims to expand Sun Pharma's portfolio and market presence.
Organon (OGN) controller sells 26,448 shares, ends direct stake
Organon & Co.'s SVP and Corporate Controller, Lynette Holzbaur, sold 26,448.366 shares of common stock at $13.3498 per share on May 6, 2026, through an open-market transaction. This amended filing clarifies that the transaction was a sale, not a purchase, and leaves her with no directly owned shares. The filing also noted the acquisition of 45.939 shares not previously required to be reported.
Organon (OGN) controller boosts stake with 26,448-share purchase
Organon & Co.'s Senior Vice President and Corporate Controller, Lynette Holzbaur, increased her stake in the company by purchasing 26,448.366 shares of common stock. The open-market transaction took place on May 6, 2026, at an average price of $13.3498 per share, bringing her direct ownership to 52,850.793 shares. This insider purchase, valued at approximately $353,080, is viewed as a positive signal for the company.
Organon & Co is the best performing healthcare stock in April
This article states that Organon & Co was the best performing healthcare stock in April.
Organon & Co stock hits 52-week high at 13.4 USD
Organon & Co (OGN) stock reached a 52-week high of $13.40, reflecting positive investor sentiment and a significant 52.85% increase over the past year. This achievement occurs despite the company reporting first-quarter results that missed Wall Street's expectations, with adjusted EPS of $0.71 and revenue of $1.46 billion, primarily due to declines in Women's Health revenue and Nexplanon sales. The company attributes the revenue decrease to unfavorable pricing, product mix, and reduced demand in key markets.
Sun Pharma to buy Organon in $11.75B all-cash deal
Sun Pharmaceutical Industries Limited (Sun Pharma) has announced plans to acquire Organon in an all-cash deal valued at $11.75 billion. This strategic acquisition aims to expand Sun Pharma's global presence, particularly strengthening its specialty commercial infrastructure and positioning it as a major player in the biosimilar market, despite recent declines in its U.S. sales. The deal, expected to close in early 2027, will combine the companies' revenues to $12.4 billion, subject to regulatory and stockholder approvals.
Organon & Co. 1Q 2026: Revenue $1.46B, EPS $0.55— 10-Q Summary
Organon & Co. reported its first-quarter 2026 results, with revenues of $1.46 billion and diluted EPS of $0.55, representing a decrease in revenue but significant increases in net income and EPS year-over-year. The company saw declines in worldwide sales due to products like Nexplanon, Singulair, and Marvelon/Mercilon, but strong growth from Emgality and Hadlima. Key corporate actions included the divestiture of Jada System and the appointment of a permanent CEO.
Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN
Mitsubishi UFJ Trust & Banking Corp significantly reduced its stake in Organon & Co. by selling 202,370 shares, decreasing its holdings by 14.1% to 1,228,223 shares valued at approximately $8.8 million. This comes as Organon missed Q1 earnings and revenue estimates, with Women's Health sales declining while Biosimilars showed growth. Analyst sentiment remains cautious, with an average "Reduce" rating and a price target of $11.40 for Organon.
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates
Organon (NYSE:OGN) missed Wall Street's Q1 CY2026 revenue and adjusted EPS estimates, with sales falling 3.5% year-on-year to $1.46 billion and adjusted EPS at $0.71. The company's revenue has been flat over the past five years and has declined annually by 1.5% over the last two years, indicating a struggle with consistent demand growth. Its adjusted operating margin also decreased significantly, reflecting rising expenses and reduced efficiency.
Organon & Co. (NYSE:OGN) Short Interest Update
Organon & Co. (NYSE:OGN) experienced a 15.9% decline in short interest in April, totaling 18,609,663 shares as of April 15th. The company recently reported Q4 earnings of $0.71 per share, missing the consensus estimate, and announced a quarterly dividend of $0.02. Analysts have a mixed view on OGN, with an average rating of "Reduce" and an average price target of $11.40.
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates
Organon (NYSE:OGN) reported a miss on Wall Street's revenue and earnings expectations for Q1 CY2026, with sales declining 3.5% year-on-year to $1.46 billion and adjusted EPS coming in 16.8% below consensus at $0.71. The company has shown a struggle with consistent revenue growth and decreasing profitability over the past several years. Analysts anticipate revenue to remain flat and full-year EPS to grow marginally in the next 12 months, highlighting ongoing challenges for the pharmaceutical firm.
Sun Pharma To Acquire Former Merck Spinoff, Organon for $11.75 Bn
Sun Pharmaceutical Industries has agreed to acquire Organon & Co. for $11.75 billion, marking one of the largest deals of 2026. This acquisition will significantly expand Sun Pharma's Innovative Medicines business, particularly in women's health and biosimilars, adding to its recent strategic acquisitions in dermatology and oncology. The combined company is projected to have revenues of $12.4 billion and is expected to close in early 2027.
Organon Reports Results for the First Quarter Ended March 31, 2026
Organon announced its first quarter 2026 financial results, with total revenue at $1.460 billion, down 4% as-reported and 9% ex-FX compared to Q1 2025. The company reported diluted EPS of $0.55 and non-GAAP Adjusted diluted EPS of $0.71. Organon also noted its pending merger with Sun Pharmaceutical Industries Limited, expected to close in early 2027, and consequently will not provide future financial guidance or host earnings calls.
Organon: Q1 Earnings Snapshot
Organon & Co. (OGN) reported a first-quarter profit of $146 million, with net income of 55 cents per share. Adjusted earnings were 71 cents per share, falling short of Wall Street's expectation of 83 cents per share. The pharmaceutical company's revenue of $1.46 billion also missed analyst forecasts of $1.47 billion.
Organon Reports Results for the First Quarter Ended March 31, 2026
Organon (NYSE: OGN) announced its first quarter 2026 results, reporting revenue of $1.460 billion, down 4% as-reported and 9% ex-FX, with diluted EPS of $0.55 and non-GAAP Adjusted diluted EPS of $0.71. The company also confirmed its pending merger with Sun Pharmaceutical Industries Limited, an all-cash transaction expected to close in early 2027, which has led to the suspension of financial guidance and quarterly earnings calls. Organon's Board of Directors declared a quarterly dividend of $0.02 per share, payable on June 11, 2026.
Organon Cancels First Quarter Earnings Call
Organon (NYSE: OGN) announced the cancellation of its first-quarter 2026 earnings conference call, previously scheduled for May 7, 2026. This decision follows its April 26, 2026 announcement of an agreement for Sun Pharmaceutical Industries Limited to acquire the company. Organon will still release its first-quarter financial results on April 30, 2026, via a press release and a subsequent Form 10-Q filing with the SEC.
Europe authorizes first PERJETA biosimilar for certain breast cancers
The European Commission has granted marketing authorization for POHERDY (pertuzumab), making it the first approved biosimilar to PERJETA in Europe. Developed by Shanghai Henlius Biotech, Inc. and Organon, POHERDY is indicated for various stages of HER2-positive breast cancer, including metastatic, neoadjuvant, and adjuvant treatments. This approval aims to improve access to quality medicines and support healthcare system sustainability in Europe.
White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon
Global law firm White & Case LLP advised Sun Pharmaceutical Industries Limited on its agreement to acquire all outstanding shares of Organon & Co. for an enterprise valuation of US$11.75 billion. Sun Pharma is a leading specialty generics company and the largest pharmaceutical company in India, while Organon is a global healthcare company with a portfolio across women's health and general medicines. The White & Case team that advised on the acquisition was led by M&A partners Keith Hallam and Matthew Barnett, and included a large team across various practice areas and regions.
Sun Pharmaceutical is buying Organon in an $11.75 billion all-cash deal
Sun Pharmaceutical has announced its acquisition of Organon in an all-cash deal valued at $11.75 billion. This significant transaction will expand Sun Pharma's portfolio and market presence, marking a major strategic move in the pharmaceutical industry. The deal represents a substantial investment by Sun Pharmaceutical to bolster its business operations.
Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase
Sun Pharmaceutical Industries is set to acquire Organon, a women's health drug developer, for $11.75 billion. This acquisition is expected to propel Sun Pharma into the top 25 global biopharma companies and make it a top three player in women's health, expanding its innovative medicines business and biosimilar offerings. The deal is projected to create a combined company with $12.4 billion in annual revenue and aims for significant synergies and growth.
Sun Pharma to Acquire Organon in $11.75 Billion Deal
Sun Pharmaceutical announced its definitive agreement to acquire Organon & Co. for $11.75 billion in an all-cash transaction. This acquisition is expected to significantly enhance Sun Pharma's global presence, particularly in dermatology and biosimilars, making the combined entity the 7th-largest biosimilar player globally. The deal aims to diversify revenue, increase innovative medicines to 27% of combined sales, and expand commercial reach to 150 countries, with the closing anticipated in early 2027.
Sun Pharma Signs Definitive Agreement to Acquire Organon
Sun Pharma has entered into a definitive agreement to acquire Organon, a global healthcare company specializing in women’s health, for $14 per share in an all-cash transaction valued at $11.75 billion. This acquisition aims to strengthen Sun Pharma's Innovative Medicines and Established Brands/Branded Generics businesses, positioning it as a top global pharmaceutical player with a strong presence in women's health and biosimilars. The transaction is expected to close in early 2027, pending regulatory and stockholder approvals.
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
Indian generics powerhouse Sun Pharma has acquired women's health leader Organon for $11.75 billion, marking the largest biopharma deal of 2026. This acquisition nearly doubles Sun Pharma's size and significantly boosts its portfolio of innovative medicines and its global standing in biosimilars, positioning it as the seventh-largest biosimilar seller worldwide. The deal aims to enhance Sun Pharma's global business and address its recent decline in U.S. sales of generic products by expanding into branded products and biosimilars.
Sun Pharma to Acquire Organon in $11.75 Billion Deal
Sun Pharmaceutical Industries is set to acquire Organon & Co. for $11.75 billion in an all-cash transaction, significantly expanding Sun Pharma's global reach and diversifying its product portfolio, particularly in women’s health and biosimilars. This deal, expected to close in early 2027, will create a combined entity with approximately $12.4 billion in annual revenue. The acquisition reflects ongoing consolidation in the pharmaceutical sector driven by pressures like pricing, patent expirations, and R&D costs.
Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.
Organon shares surged after India's Sun Pharmaceutical Industries announced an agreement to acquire the women's healthcare company for $11.75 billion. This acquisition highlights the current trend of increasing mergers and acquisitions within the pharmaceutical sector.
India’s Sun Pharma to buy US-listed Organon in about $11.8 billion deal
Sun Pharmaceutical Industries is set to acquire U.S. drugmaker Organon & Co in an all-cash deal worth approximately $11.75 billion, including debt. This acquisition marks the largest overseas purchase by an Indian pharmaceutical company and aims to bolster Sun Pharma's presence in high-margin specialty medicines, particularly in areas like dermatology, oncology, and obesity, while also expanding its reach into new markets like China and Brazil. The deal is expected to double Sun's revenue and EBITDA, significantly strengthening its women's health portfolio and marking its entry into biosimilars.
Sun Pharma shares jump 7% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal
Sun Pharmaceutical Industries is set to acquire U.S.-based Organon & Co in an all-cash deal worth $11.75 billion, causing Sun Pharma's shares to jump 7%. This acquisition, valuing Organon at $14.00 per share, is expected to boost Sun Pharma's revenues to $12.4 billion, positioning it among the top 25 global pharmaceutical companies. Organon, specializing in women's health and biosimilars, will significantly enhance Sun Pharma's innovative medicines portfolio and global market reach, despite the associated financial nuances of integration and higher leverage.
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited has revealed its definitive agreement to acquire Organon & Co. for US$14.00 per share in an all-cash transaction, valuing Organon at an enterprise valuation of US$11.75 billion. This acquisition is poised to make Sun Pharma a stronger player in established brands/branded generics and a top-10 global player in biosimilars, significantly expanding its global footprint and enhancing its innovative medicines business. The transaction, approved by both companies' boards, is expected to close in early 2027, transforming Sun Pharma into one of the top 25 global pharmaceutical companies with combined revenues of US$12.4 billion.
Organon climbs amid reports of $13B buyout bid from Sun Pharma
Organon & Co. (OGN) stock rose significantly following a report of a potential $13 billion buyout bid from India's Sun Pharmaceutical Industries, according to The Economic Times. While Sun Pharma neither confirmed nor denied the report, the acquisition would significantly expand its women's health and biosimilars portfolio.
Organon (OGN) Takeover Bid Climbs to $13B, Shares Soar 30.9%
Organon (OGN) shares surged by 30.93% after news that Sun Pharmaceuticals increased its takeover offer to $13 billion from an initial $12 billion. Sun Pharma has secured backing from major global lenders for the acquisition. Organon, spun off from Merck in 2021, specializes in women's health therapies and recently reported positive results from a late-stage clinical trial for its VTAMA cream.
Sun Pharma: $11.75 Billion Organon Acquisition Expands Global Scale And Women’s Health Leadership
Sun Pharma announced a definitive agreement to acquire Organon & Co. for $11.75 billion, significantly expanding its global footprint, particularly in women's health and biosimilars. This all-cash transaction is expected to nearly double Sun Pharma's EBITDA and cash flow, positioning it among the top 25 global pharmaceutical companies. The acquisition aims to enhance geographic reach, leverage Organon's established infrastructure, and drive long-term value creation through integrated operations and product pipelines.
India’s biggest pharma firm said to mull bid for New York-listed Organon
The article reports that India's largest pharmaceutical company is considering a bid for Organon, a New York-listed pharmaceutical firm. This potential acquisition could significantly expand the Indian company's global presence. The details of the potential bid and its implications for both companies are currently under consideration.
India’s biggest pharma firm said to mull bid for New York-listed Organon
The article reports that India's largest pharmaceutical company is reportedly considering a bid for Organon, a New York-listed firm. The potential acquisition would signify a major international expansion for the Indian pharma giant. Further details about the bid were not provided in this brief snippet.
Organon CEO stands down amid contraceptive sales malpractice probe
Organon's CEO has stepped down as the company faces a probe into contraceptive sales malpractice. The company is dealing with the repercussions of these allegations.
Organon Stock Jumps as Sun Pharma’s Reported $13 Billion Bid Puts OGN in Takeover Spotlight
Organon & Co. shares surged following a report that Sun Pharmaceutical Industries made a $13 billion all-cash takeover bid, significantly above Organon's current market value. The offer, backed by major banks, suggests a competitive race for the women's health drugmaker, despite potential concerns over the debt load for Sun Pharma. Organon, with its portfolio across women's health, established medicines, and biosimilars, is now trading like a takeover target ahead of its first-quarter earnings report.
Organon stock climbs amid buyout rumors (OGN:NYSE)
Organon (OGN) shares surged approximately 30% in premarket trading following reports that India's Sun Pharmaceutical Industries has submitted a $13 billion binding offer to acquire the U.S. drugmaker. This potential acquisition would mark Sun Pharma's largest-ever merger and acquisition deal. The news has led to significant investor interest in Organon stock.
Organon Stock Surges As Traders Bet On $12B Takeover
Organon & Co. (OGN) stock surged over 21% following reports of a potential $12 billion all-cash acquisition by Sun Pharmaceutical, with Grunenthal and private equity firms also rumored to be interested. This M&A speculation, coupled with the strong recommendation for Organon's VTAMA cream in pediatric atopic dermatitis guidelines, has driven significant investor interest and volatility. BNP Paribas reiterated an Outperform rating, citing a potential $15 per share takeout value.
Sun Pharma moves ahead with $13 billion Organon bid amid global expansion push: Report
Sun Pharmaceutical Industries has submitted a binding offer of nearly $13 billion for US-based Organon & Co. This proposed acquisition is part of Sun Pharma's strategy to expand beyond its role as an Indian generics leader into a global branded and innovation-driven drugmaker. The deal could face competition from Swedish private equity firm EQT and German pharmaceutical company Gruenthal.
Organon (OGN) Is Up 8.4% After VTAMA Wins Key Steroid-Free Role In New Pediatric Guidelines
Organon & Co. (OGN) saw an 8.4% stock increase after its VTAMA cream received a strong recommendation in the American Academy of Dermatology’s new pediatric atopic dermatitis guidelines. VTAMA is recognized as the only steroid-free topical supported by high-certainty evidence for children aged 2 and older. This endorsement enhances VTAMA’s clinical profile, reinforcing Organon’s newer-therapy portfolio and supporting its pivot towards higher-margin growth assets, despite ongoing challenges from legacy products and debt.
